This biotech company has a track record of commercializing products and delivering growth. It also has strengths in research and development. When you think of biotech companies, you may think of ...

There are hundreds of biotechnology companies today that have never commercialized a drug. For many years, the standard approach in the industry has been to advance the science, prove the asset, and ...

It is nearly eight years since healthcare and biotech investor Sam Isaly abruptly stepped down from OrbiMed, the managers of the Worldwide Healthcare Trust (LSE: WWH). In the 22 years in which he was ...

For years, public debate around U.S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing. Far less attention has been paid to a ...

Arthur Herman’s op-ed, “America Is the Sole Superpower Again,” (Jan. 15) asserts that China is “sliding into a distant second place” in the battle for economic, military and technological supremacy.

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...

Biotech IPOs hit lowest level in over a decade in 2025 Investors focus on biotechs with mature pipelines and positive trial data Lower interest rates and capital inflows expected to boost sector Jan ...

The green shoots suggesting a comeback was in sight for biotech stocks last year have mostly grown into proverbial flowering plants—but one company’s precipitous year-over-year decline in market ...

Emily A. Buddle has received funding from the Department of Primary Industries and Regions South Australia, the Australian Research Council and Meat and Livestock Australia. She is currently an ...

After five years, Nido Biosciences has reached the end of the road, closing its doors after its lead neurological disease candidate disappointed in a midstage study. Founded by 5AM Ventures’ 4:59 ...

Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Boston CEOs point to a rise in ...